The SPDR S&P Biotech ETF (XBI) closed at $168.26 on August 28, 2026, slipping 0.08% over the prior 24 hours as investors locked in modest gains following a strong recent run.
Despite the slight daily pullback, the fund has posted a gain of 2.99% over the past seven days, reflecting sustained buying interest across the biotech sector in recent weeks.
The 30-day performance tells a notably stronger story, with XBI up 12.32% over that stretch — a substantial move that underscores the momentum that has built up in biotech equities heading into late August.
Market capitalization data for the fund was not available as of the close of trading.
